Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0202
EDITORIAL
|
Inhibiting mTOR and VEGF signaling in pancreatic neuroendocrine tumors |
|
Affiliation: Christos Katsios, Associate Professor of Surgery, Department of Surgery, University Hospital of Ioannina, Ioannina, TK 45110, Greece.
Tel: +2651099696
E-mail: chkatsios@gmail.com |
Abstract
Signal transduction drugs, called also targeted agents, have arose great expectations for improving oncological outcomes of patients with solid tumors over the last decade. However, for most targeted drugs developed, with a few exceptions such as trastuzumab or more recently vemurafenib (PLX4032), no overall survival benefit could be obtained. Everolimus and sunitinib have provided substantial antitumor activity in pre-clinical and small clinical studies in the treatment of patients with metastatic pancreatic neuroendocrine tumors. Here I discuss the results of phase 3 randomized clinical trials and their impact on routine clinical practice.
(Citation: Gastric & Breast Cancer 2012; 11(1): 13-19 Rolex Replica Watches)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 30 December 2011 |
|
